Recent advances in understanding the mechanism of action of bisphosphonates

Fraser Coxon, Keith Thompson, Michael John Rogers

Research output: Contribution to journalLiterature review

190 Citations (Scopus)

Abstract

Bisphosphonates (BPs) are widely used in the treatment of diseases associated with excessive osteoclast-mediated bone resorption, such as osteoporosis. Although several years ago the molecular target of the potent nitrogen-containing BPs (N-BPs) was identified as farnesyl diphosphate synthase, an enzyme in the mevalonate pathway, recent data have shed new light on the precise mechanism of inhibition and demonstrated that the acute-phase reaction, an adverse effect of N-BPs, is also caused by inhibition of this enzyme. In addition, the identification of BP analogues that inhibit different enzymes in the mevalonate pathway could lead to the development of novel inhibitors of bone resorption with potential applications in the treatment of bone disease.

Original languageEnglish
Pages (from-to)307-312
Number of pages5
JournalCurrent Opinion in Pharmacology
Volume6
Issue number3
Early online date2 May 2006
DOIs
Publication statusPublished - Jun 2006

Keywords

  • nitrogen-containing bisphosphonates
  • RAB gernaylgeranyl transferase
  • farnesyl diphosphate synthase
  • acute-phase response
  • activation in-vitro
  • T-cell-activation
  • bone-resorption
  • mevalonate pathway
  • ATP analog
  • inhibition

Cite this

Recent advances in understanding the mechanism of action of bisphosphonates. / Coxon, Fraser; Thompson, Keith; Rogers, Michael John.

In: Current Opinion in Pharmacology, Vol. 6, No. 3, 06.2006, p. 307-312.

Research output: Contribution to journalLiterature review

Coxon, Fraser ; Thompson, Keith ; Rogers, Michael John. / Recent advances in understanding the mechanism of action of bisphosphonates. In: Current Opinion in Pharmacology. 2006 ; Vol. 6, No. 3. pp. 307-312.
@article{a68e7e9cd0854937a8ad64542609df0e,
title = "Recent advances in understanding the mechanism of action of bisphosphonates",
abstract = "Bisphosphonates (BPs) are widely used in the treatment of diseases associated with excessive osteoclast-mediated bone resorption, such as osteoporosis. Although several years ago the molecular target of the potent nitrogen-containing BPs (N-BPs) was identified as farnesyl diphosphate synthase, an enzyme in the mevalonate pathway, recent data have shed new light on the precise mechanism of inhibition and demonstrated that the acute-phase reaction, an adverse effect of N-BPs, is also caused by inhibition of this enzyme. In addition, the identification of BP analogues that inhibit different enzymes in the mevalonate pathway could lead to the development of novel inhibitors of bone resorption with potential applications in the treatment of bone disease.",
keywords = "nitrogen-containing bisphosphonates, RAB gernaylgeranyl transferase, farnesyl diphosphate synthase, acute-phase response, activation in-vitro, T-cell-activation, bone-resorption, mevalonate pathway, ATP analog, inhibition",
author = "Fraser Coxon and Keith Thompson and Rogers, {Michael John}",
year = "2006",
month = "6",
doi = "10.1016/j.coph.2006.03.005",
language = "English",
volume = "6",
pages = "307--312",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Recent advances in understanding the mechanism of action of bisphosphonates

AU - Coxon, Fraser

AU - Thompson, Keith

AU - Rogers, Michael John

PY - 2006/6

Y1 - 2006/6

N2 - Bisphosphonates (BPs) are widely used in the treatment of diseases associated with excessive osteoclast-mediated bone resorption, such as osteoporosis. Although several years ago the molecular target of the potent nitrogen-containing BPs (N-BPs) was identified as farnesyl diphosphate synthase, an enzyme in the mevalonate pathway, recent data have shed new light on the precise mechanism of inhibition and demonstrated that the acute-phase reaction, an adverse effect of N-BPs, is also caused by inhibition of this enzyme. In addition, the identification of BP analogues that inhibit different enzymes in the mevalonate pathway could lead to the development of novel inhibitors of bone resorption with potential applications in the treatment of bone disease.

AB - Bisphosphonates (BPs) are widely used in the treatment of diseases associated with excessive osteoclast-mediated bone resorption, such as osteoporosis. Although several years ago the molecular target of the potent nitrogen-containing BPs (N-BPs) was identified as farnesyl diphosphate synthase, an enzyme in the mevalonate pathway, recent data have shed new light on the precise mechanism of inhibition and demonstrated that the acute-phase reaction, an adverse effect of N-BPs, is also caused by inhibition of this enzyme. In addition, the identification of BP analogues that inhibit different enzymes in the mevalonate pathway could lead to the development of novel inhibitors of bone resorption with potential applications in the treatment of bone disease.

KW - nitrogen-containing bisphosphonates

KW - RAB gernaylgeranyl transferase

KW - farnesyl diphosphate synthase

KW - acute-phase response

KW - activation in-vitro

KW - T-cell-activation

KW - bone-resorption

KW - mevalonate pathway

KW - ATP analog

KW - inhibition

U2 - 10.1016/j.coph.2006.03.005

DO - 10.1016/j.coph.2006.03.005

M3 - Literature review

VL - 6

SP - 307

EP - 312

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 3

ER -